TerraPower Isotopes Bellwether Laboratory — Philadelphia

A shuttered oil refinery in South Philadelphia is becoming the world’s largest source of a cancer-fighting isotope. TerraPower Isotopes, the radiopharmaceutical arm of the Bill Gates-backed nuclear firm, is building a $450 million, 250,000-square-foot cGMP manufacturing plant inside the Bellwether District, the 1,300-acre industrial redevelopment that replaced the old Philadelphia Energy Solutions complex. Gilbane Building Company leads preconstruction and construction of the core and shell.

Project Scope

The facility will produce actinium-225, an alpha-emitting isotope used in targeted radiopharmaceutical therapy for advanced cancers. Supply has been the bottleneck for the entire field: global output today is measured in a few curies a year, sourced largely from Cold War-era thorium-229 stockpiles held at Oak Ridge National Laboratory in Tennessee. TerraPower expects the Philadelphia plant to raise worldwide production capacity roughly twentyfold when it comes online in 2029.

Building it is a radiopharmaceutical problem before it’s a construction problem. cGMP isotope manufacturing means hot cells, heavy shielding, redundant HVAC with cascading pressure zones, and a clean-room envelope that has to hold through decades of regulated operation. The core-and-shell package Gilbane is delivering has to anticipate all of that, on a brownfield with a century of refining history under it. Site remediation and geotechnical conditions on the former refinery footprint drive much of the early schedule.

TerraPower Isotopes expects to employ about 225 people in Philadelphia once the plant opens in the second half of 2029.

Why It Matters

Philadelphia has spent five years trying to convert 1,300 acres of hydrocarbon infrastructure into life sciences and logistics space, and the pitch has always been that the site’s power, rail and water made it a natural fit for heavy manufacturing. This is the proof. A nuclear-adjacent pharmaceutical plant is about as far from a warehouse shell as an industrial tenant gets, and it lands the district a second anchor tenant with a 20-year operating horizon.

For contractors, the project is a marker of where advanced-manufacturing work is heading. Semiconductor fabs got the attention and the CHIPS money; radiopharmaceutical and biologics plants are quietly running the same playbook, with similar shielding, containment and commissioning demands, at a fraction of the square footage. The trade stack is narrower and deeper, and the qualified subcontractor pool for hot-cell and shielded-containment work in the Northeast is small enough that early procurement decides the schedule.

Project Team & Details